T cell epitope identification in Remicade® and Humira® using the REVEAL® Immunogenicity System

Matthew Frayne

7 February 2012

PROIMMUNE
www.proimmune.com

REVEAL® Immunogenicity Case Study 1

- **Remicade® (infliximab)**
  - Chimeric monoclonal IgG1 antibody (human constant and murine variable regions)
  - Binds to soluble and transmembrane forms of TNFα and inhibits binding of TNFα with its receptors
  - Indication: RA, Crohn's disease, Ulcerative Colitis, Ankylosing spondilitis
  - **Immunogenicity:** 10-50% of patients develop low titer neutralizing Abs against (depending on indication)

- **Humira® (adalimumab)**
  - IgG1 antibody with human derived heavy and light chain variable regions and human IgG1:k constant regions generated by phage-display
  - **Immunogenicity:** 5%-20% of patients develop low titer neutralizing Abs (depending on indication)

PROIMMUNE
www.proimmune.com

CD4⁺ T Cell Epitope Discovery and Characterization Strategy

Remicade®

Humira®

Library of overlapping peptides from variable regions

15-mers offset by 3 amino acids

1. **CFSE T cell proliferation assay**
2. ***In vitro* REVEAL® MHC-peptide binding assay**

PROIMMUNE
www.proimmune.com

CFSE T Cell Proliferation Assays

- **CD8$^+$ depleted** PBMCs from minimum 40 HLA-typed individuals representing tissue type distribution in the global population

- High resolution tissue typed for HLA-DR, -DP and –DQ

- CFSE staining of PBMCs at the start of the assay

- Co-culture of PBMCs with synthetic peptides

- T cell proliferation is measured over 7 day period by CFSE flow cytometry assay in sextuplicate analysis

- **Does the peptide elicit a significant functional response?**

PROIMMUNE
www.proimmune.com

CFSE T Cell Proliferation Assays

- ## Flow cytometry assay that measures only live CD4$^+$ cells

- ## Cell Division Index = [C/(C+D)] / [A /(A+B)]

% proliferating to peptide / % proliferating in negative control

- ## A significant response is determined as p<0.05 by ANOVA analysis, CDI>2 and 2 SEM above background

PROIMMUNE
www.proimmune.com

T Cell Proliferation – Heavy Chain

Remicade® Heavy Chain

Humira® Heavy Chain

CDR1 CDR2 CDR3

% Antigenicity

Peptide Number

PROIMMUNE
www.proimmune.com

T cell Proliferation – Light Chain

PROIMMUNE
www.proimmune.com

Characterization of HLA-Associations

- **A number of epitopes with functional responses identified and characterized from the variable domains of Remicade® and Humira®**

- **What are the HLA associations of these epitopes?**

- **What is the global immunogenicity impact of each epitope?**

PROIMMUNE
www.proimmune.com

REVEAL® Binding Assay

2 components:

- REVEAL® Binding Assay (Complex formation)
- REVEAL® Stability Assay measured after 24h at 37°C (Complex dissociation)

No signal

Signal

Peptides with longer off-rates (>3h) are considered good enough to give rise to immunogenicity*

*Peter *et al.* (2001) *Vaccine* 19: 4121-4129

*Burshtyn and Barber (1993) *J Immunol.* 151: 3082-3093

*van der Burg *et al.* (1996) *J Immunol.* 156: 3308-3314

PROIMMUNE
www.proimmune.com

REVEAL® MHC Alleles

Class II

DPA1*01:03 + DPB1*01:01	DRA1*01:01 + DRB1*01:01	DRA1*01:01 + DRB1*15:02
DPA1*01:03 + DPB1*02:01	DRA1*01:01 + DRB1*15:01	DRA1*01:01 + DRB1*15:03
DPA1*01:03 + DPB1*03:01	DRA1*01:01 + DRB1*03:01	DRA1*01:01 + DRB1*16:01
DPA1*01:03 + DPB1*04:01	DRA1*01:01 + DRB1*04:01	DRA1*01:01 + DRB1*16:02
DPA1*01:03 + DPB1*04:02	DRA1*01:01 + DRB1*11:01	DRA1*01:01 + DRB3*02:02
DPA1*01:03 + DPB1*05:01	DRA1*01:01 + DRB1*13:01	DRA1*01:01 + DRB3*03:01
DPA1*02:01 + DPB1*01:01	DRA1*01:01 + DRB1*07:01	DRA1*01:01 + DRB5*01:01
DPA1*02:01 + DPB1*02:01	DRA1*01:01 + DRB1*01:02	DQA1*01:01 + DQB1*05:01
DPA1*02:01 + DPB1*03:01	DRA1*01:01 + DRB1*04:02	DQA1*05:01 + DQB1*03:01
DPA1*02:01 + DPB1*04:01	DRA1*01:01 + DRB1*04:04	DQA1*01:02 + DQB1*05:02
DPA1*02:01 + DPB1*04:02	DRA1*01:01 + DRB1*04:05	DQA1*01:02 + DQB1*06:02
DPA1*02:01 + DPB1*05:01	DRA1*01:01 + DRB1*04:07	DQA1*03:01 + DQB1*03:02
DPA1*02:01 + DPB1*06:01	DRA1*01:01 + DRB1*04:08	DQA1*01:02 + DQB1*06:04
DPA1*02:01 + DPB1*09:01	DRA1*01:01 + DRB1*08:04	DQA1*05:01 + DQB1*02:01
DPA1*02:01 + DPB1*11:01	DRA1*01:01 + DRB1*09:01	DQA1*02:01 + DQB1*02:02
DPA1*02:01 + DPB1*13:01	DRA1*01:01 + DRB1*10:01	DQA1*03:01 + DQB1*03:01
DPA1*02:01 + DPB1*14:01	DRA1*01:01 + DRB1*11:02	DQA1*02:01 + DQB1*03:03
DPA1*02:01 + DPB1*15:01	DRA1*01:01 + DRB1*11:03	DQA1*03:03 + DQB1*03:03
DPA1*02:01 + DPB1*17:01	DRA1*01:01 + DRB1*11:04	

PROIMMUNE
www.proimmune.com

REVEAL® Binding Assay

			DRA*01:01;DRB1*11:01			
Peptide I.D.	MHC-Binding Score at 0 h	MHC-Binding Score at 24 h	Graphical Representation of REVEAL™ Score	Stability Index	Graphical Representation of Stability Index	
1. AKNSLYLQMNSLRAE	88.7	82.7		106.4		
2. SLYLQMNSLRAEDTA	99.3	72.5		52.5		
3. LQMNSLRAEDTAVYY	2.8	1.8		1.0		
4. NSLRAEDTAVYYCAK	4.2	0.0		0.0		
5. RAEDTAVYYCAKVSY	38.1	0.3		1.3		
6. AEDTAVYYCAKVSYL	36.6	0.6		1.5		
7. TAVYYCAKVSYLSTA	46.2	10.9		5.3		
8. YYCAKVSYLSTASSL	45.2	18.7		8.5		
9. AKVSYLSTASSLDYW	34.3	7.1		3.6		
10. SYLSTASSLDYWGQG	2.8	0.0		0.0		
11. STASSLDYWGQGTLV	0.0	0.0		0.0		
12. SSLDYWGQGTLVTVS	6.8	0.0		0.0		
13. SLDYWGQGTLVTVSS	13.7	0.0		0.0		
14. DIQMTQSPSSLSASV	34.8	0.4		1.3		
15. MTQSPSSLSASVGDR	0.0	0.0		0.0		
16. SPSSLSASVGDRVTI	0.0	0.0		0.0		
17. SLSASVGDRVTITCR	0.0	0.0		0.0		
18. ASVGDRVTITCRASQ	26.7	1.3		1.5		
19. GDRVTITCRASQGIR	38.9	9.6		4.6		
20. VTITCRASQGIRNYL	13.7	2.7		1.4		
Positive Control	100.0 +/- 6.6	94.0 +/- 13.0		114.9 +/- 12.6		
Intermediate Control	13.8 +/- 3.5	13.8 +/- 3.2		16.6 +/- 4.1		

Graphical Representation of REVEAL™ Score axis: 20 40 60 80

Stability Index axis: 6 120

Stability Guide: LOW   HIGH   VERY HIGH

Representative analysis of a single allele (DRB1*11:01) from the
C-terminus of Humira® heavy chain (incorporating the CDR3 region) and
N-terminus of the light chain

PROIMMUNE
www.proimmune.com

T Cell Proliferation – Heavy Chain

Remicade® Heavy Chain

CDR1 CDR2 CDR3

Humira® Heavy Chain

% Antigenicity

Peptide Number

PROIMMUNE
www.proimmune.com

HLA Restriction of Functional T Cell Epitopes

Analysis of Peptide 32 (GVYYCSRNYYGSTYD) from Remicade® Heavy Chain CDR3

Donor ID	DRB1		DQB1		DPB1	
D387	*13:01	*15:01	*06:03	*06:02	*13:01	*01:01
D400	*03:01	*16:01	*02:01	*05:02	*04:01	*04:01
D401	*04:04	*15:01	*06:02	*03:02	*04:01	*04:01
D415	*03:01	*07:01	*02:02	*02:01	*04:01	*02:01
D426	*04:01	*13:02	*03:02	*06:05	*04:02	*10:01

Analysis of Peptide 107 (TAVYYCAKVSYLSTA) from Humira® Heavy Chain CDR3

Donor ID	DRB1		DQB1		DPB1	
D393	*03:01	*04:04	*02:01	*03:02	*02:02	*03:01
D400	*03:01	*16:01	*02:01	*05:02	*04:01	*04:01
D407	*01:01	*03:01	*02:01	*05:01	*04:01	*04:02
D413	*01:03	*01:01	*05:01	*05:01	*04:01	*04:02
D415	*03:01	*07:01	*02:02	*02:01	*04:01	*02:01
D424	*01:03	*15:01	*05:01	*06:02	*04:01	*04:01
D430	*01:01	*11:04	*03:01	*05:01	*04:01	*04:02

Key

Red – No binding to MHC

Green – Stable binding

Yellow – Weak affinity binding

Grey – Untested

PROIMMUNE
www.proimmune.com

Conclusions

- **Remicade®**
  - Numerous epitopes identified and characterized from the whole variable domain
  - Weak to intermediate strength of proliferative responses
  - Restricted HLA association

- **Humira®**
  - Fewer epitopes, largely restricted to the CDR regions
  - Strong proliferative responses
  - Promiscuous HLA binding

- **Which are the immunodominant epitopes in patients with ADA responses?**

- **Are these peptides processed and presented to the immune system?**

PROIMMUNE
www.proimmune.com

T Cell Epitope Antigenicity Profiling

Antigen Processing

HLA-peptide Binding

T Cell Function

PROIMMUNE
www.proimmune.com

ProPresent® workflow

VGSDWRFLRGYHQYA
VGSDWRFLRGYHQYAYGD
 GSDWRFLRGYHQYA
...

PROIMMUNE
www.proimmune.com

Integrated Approaches for Antigenicity Characterization

- ## Immunogenicity is a complex issue!

- ## No single approach is perfect

- ## Multiple approaches to aid prediction of clinical immunogenicity and therapeutic outcomes

- **T Cell Proliferation and REVEAL® Binding Assays**
  - Detailed epitope identification and characterization

- **ProPresent**
  - Whole protein epitope processing and HLA-associated presentation
  - Post-translational and formulation analysis

- **DC-T Proliferation**
  - Comparison of whole protein antigenicity in Lead Selection

PROIMMUNE
www.proimmune.com

Acknowledgements:

Helen Barnby-Porritt, Cathy Napper, Hella Schmidt, Aoife Conneely and Sarah McCrory.

For further information please contact:

**Matthew Frayne
Immunology Sales Specialist
ProImmune Limited
mfrayne@proimmune.com
Tel: +44 870 042 7279
www.proimmune.com**

PROIMMUNE
www.proimmune.com

Whole Protein Immunogenicity

- **MDDCs generated from human tissue bank**

- **Pulsed with Remicade® or Humira®**

- **Co-cultured with autologous PBMCs labelled with CFSE**

PROIMMUNE
www.proimmune.com